An observational study in Atheroma; Carotid Artery and Atheromatosis, sponsored by Université Catholique de Louvain. Not yet recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-27.
Sponsored by Université Catholique de Louvain · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The leading cause of death is cardiovascular diseases in occidental countries. Of those, atherosclerosis is the major contributor to this burden being notably responsible for strokes and myocardial infarctions. The genesis of atherosclerosis is linked to both lipid accumulation and inflammation in the vascular wall of major arteries. One of the major pathways of inflammation is the TGF-beta axis which is at least partially regulated by the GARP protein. It has been investigated mostly in cancer biology but data in cardiovascular disease is lacking. Thus, the investigators aim to characterize the contribution of this protein by investigating its expression in tissue from patients with atherosclerosis, the carotid or femoral plaque representing a good source of residual material adequate for research purpose. The main cells expressing the GARP protein are the platelets and the T regulating cells which will be the main focus.
260 studies on the registry are indexed under Carotid Artery Diseases; 60 are open to participants now.
This study's planned enrollment of 200 is close to the median of 200 across 115 observational studies indexed under Carotid Artery Diseases.
Browse Carotid Artery Diseases studies →Université Catholique de Louvain is the lead sponsor of 155 studies on the registry; 60 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will comprise patients undergoing femoral or carotid endarterectomy in our tertiary care center (Cliniques Universitaires Saint-Luc) for atherosclerotic disease who do not meet exclusion criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This group includes patients with significant atherosclerotic burden justifying a surgical intervention of carotid or femoral endarterectomy.
Other: Tissue sample and data collection
Tissue sample and data collection
GARP Expression in Platelets
The number of cells/area expressing the GARP protein will be assessed
Time frame: Throughout the entire study, approximately during 3 years
GARP Expression T Regulating Cells
The number of cells expressing GARP will be assessed as a number of cells / area
Time frame: Throughout the entire study, approximately during 3 years
GARP Expression General
The type of cells expressing GARP will be assessed as a number of cells / area
Time frame: Throughout the entire study, approximately during 3 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Jan 2029, 35 months later.
Of 45 observational studies under Carotid Artery Diseases, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 94. This study's planned 35 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Université Catholique de Louvain →